Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for Carbetocin Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product in the market [1] Group 1: Product Information - Carbetocin Injection is indicated for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and gynecology [1] - The product shows notable efficacy in treating urinary system conditions and can also be used for the prevention and treatment of surgical bleeding [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing of Carbetocin Injection, which is indicated for various bleeding disorders in the urinary system, upper digestive tract, respiratory tract, and gynecology [1] Group 1 - The approved product, Carbetocin Injection, is effective for urinary system conditions and can also be used for the prevention and treatment of surgical bleeding [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing of Caroverine Sodium Injection, which is expected to enhance its product line and market competitiveness [1] Summary by Categories Product Approval - The company has obtained the drug registration certificate for Caroverine Sodium Injection, which is primarily used for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and obstetrics and gynecology [1] Market Potential - The estimated domestic market sales for Caroverine Sodium Injection in 2024 is approximately 250 million yuan [1] R&D Investment - The company has invested around 7.12 million yuan in the research and development of this project [1]

Core Viewpoint - Huahai Pharmaceutical's stock has experienced a decline of 5.04% over the past three days, closing at 22.43 CNY per share with a market capitalization of 33.583 billion CNY [1] Company Overview - Zhejiang Huahai Pharmaceutical Co., Ltd. was established on February 28, 2001, and listed on March 4, 2003. The company specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The revenue composition of the company is as follows: finished drug sales account for 61.86%, raw materials and intermediates sales for 36.75%, other sales for 0.78%, and technical services for 0.62% [1] Fund Holdings - According to data, one fund under Jiashi Fund holds a significant position in Huahai Pharmaceutical. Jiashi Xinhe One-Year Holding Period Mixed A (008664) held 50,300 shares in the second quarter, representing 0.39% of the fund's net value, making it the sixth-largest holding [2] - The fund has incurred a floating loss of approximately 26,700 CNY today, with a total floating loss of 59,900 CNY during the three-day decline [2] Fund Manager Information - The fund manager of Jiashi Xinhe One-Year Holding Period Mixed A (008664) is Yang Yechao, who has been in the position for 9 years and 303 days. The total asset size of the fund is 1.878 billion CNY [3] - During Yang Yechao's tenure, the best fund return was 40.38%, while the worst return was -4.07% [3]

Group 1 - The core point of the article is that Huahai Pharmaceutical (600521) announced a non-public offering of shares, with a total of 41,152,263 shares to be listed [1] - The subscription method for the shares is offline, indicating a targeted approach to raising capital [1] - The listing date for the shares is set for September 25, 2025, marking a future event for investors to consider [1]

Group 1 - Company Huahai Pharmaceutical announced that approximately 41.15 million restricted shares will be unlocked and listed for trading on September 25, 2025, accounting for about 2.75% of the company's total share capital [1] - For the year 2024, the revenue composition of Huahai Pharmaceutical is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - The current market capitalization of Huahai Pharmaceutical is 34.4 billion yuan [2]

浙江华海药业股份有限公司 证券代码：600521 证券简称：华海药业 公告编号：临 2025-102 号 债券代码：110076 债券简称：华海转债 关于向特定对象发行股票限售股上市流通公告 本次股票上市流通日期为2025 年 9 月 25 日。 一、本次限售股上市类型 （一）向特定对象发行股票同意注册情况 2024 年 4 月 2 日，浙江华海药业股份有限公司（以下简称"公司"）收到中国 证券监督管理委员会（以下简称"中国证监会"）出具的《关于同意浙江华海药业 股份有限公司向特定对象发行股票注册的批复》（证监许可[2024]480 号），同意公 司向特定对象发行股票的注册申请。 （二）股份登记情况 2025 年 3 月 25 日，公司向特定对象发行股票新增的 41,152,263 股股份在中 国证券登记结算有限责任公司上海分公司（以下简称"中国结算上海分公司"）办 理完毕股份登记、托管及限售手续。本次发行完成后，公司总股本由 1,466,755,541 股变更为 1,507,907,804 股。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完 ...

浙商证券股份有限公司（以下简称"保荐机构"）作为浙江华海药业股份有 限公司（以下简称"华海药业"或"公司"）向特定对象发行股票的保荐机构， 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第11号——持续督导》等法律法规的相关规定， 对华海药业向特定对象发行股票限售股上市流通的事项进行了核查，核查情况及 核查意见如下： 关于浙江华海药业股份有限公司 向特定对象发行股票限售股上市流通的核查意见 一、本次限售股上市类型 （一）向特定对象发行股票同意注册情况 浙商证券股份有限公司 二、本次限售股形成后至今公司股本数量变化情况 2024 年 4 月 2 日，华海药业收到中国证券监督管理委员会（以下简称"中 国证监会"）出具的《关于同意浙江华海药业股份有限公司向特定对象发行股票 注册的批复》（证监许可[2024]480 号），同意公司向特定对象发行股票的注册 申请。 （二）股份登记情况 2025 年 3 月 25 日，公司向特定对象发行股票新增的 41,152,263 股股份在中 国证券登记结算有限责任公司上海分公司（以下简称"中国结算上海分公司"） 办理完毕股份 ...

Core Viewpoint - Huahai Pharmaceutical announced that 41.1523 million restricted shares will be listed for circulation on September 25, 2025, following approval from the China Securities Regulatory Commission [1] Summary by Relevant Sections - **Share Issuance Details** - The issuance involves 41.1523 million restricted shares, which will be listed for circulation after a 6-month lock-up period [1] - The shares were registered with the China Clearing Shanghai Branch on March 25, 2025 [1] - **Shareholder Information** - The issuance involves 14 shareholders who have all fulfilled their lock-up commitments [1] - The company has undergone changes in its share capital, including share buybacks and convertible bonds conversion [1] - **Regulatory Approval** - The issuance has received approval from the China Securities Regulatory Commission, and the sponsoring institution has no objections to the listing of these restricted shares [1]

Group 1 - Shudao Equipment's subsidiary signed a construction contract worth 24.68 million yuan for a hydrogen fuel cell manufacturing base project [1] - Zhongliang Technology received a land acquisition compensation of 30 million yuan from the government [2] - Palm Holdings won a bid for a high-standard farmland construction project in Lankao County, with a contract value of 433 million yuan, accounting for 14.12% of the company's audited revenue for 2024 [3] Group 2 - Changchun Yidong's subsidiary received a government subsidy of 2.85 million yuan, which is 122.78% of the company's audited net profit for the last fiscal year [4] - Wuzhou Transportation successfully issued 200 million yuan in medium-term notes with an interest rate of 2.10% [5][6] - Tiandi Source's subsidiary plans to apply for a trust loan of up to 500 million yuan from related parties [8] Group 3 - Tiandi Source's subsidiary acquired a residential land use right in Xi'an for 2.015 billion yuan [9] - Opcon Vision received a medical device registration certificate for its ultrasonic nebulizer [11] - Jingjiawei announced the resignation of its vice president due to personal reasons [13] Group 4 - Fulinh Precision's subsidiary received a prepayment of 1.5 billion yuan from CATL for securing lithium iron phosphate material supply [15] - Yunzhu Technology's subsidiary received a government subsidy of 20.12 million yuan [16] - Kehua Bio's ferritin test kit received a medical device registration certificate [17] Group 5 - Jinghua Pharmaceutical's medical sodium alginate wound dressing received a medical device registration certificate [18] - Lingwei Technology established a wholly-owned subsidiary with a registered capital of 1 million yuan [19] - Sanwei Co. won a bid for concrete sleeper procurement projects worth 158 million yuan [20] Group 6 - Shanghai Pharmaceuticals' Nicardipine tablets passed the consistency evaluation for generic drugs [21] - Lushan New Materials increased its idle fund management limit to 750 million yuan [24] - Huayi Technology announced the retirement of a core technical staff member [25] Group 7 - Yingli Environment plans to use up to 300 million yuan of idle raised funds for cash management [30] - Yong'an Forestry plans to develop a national reserve forest project in Putian, Fujian, with an estimated investment of 154 million yuan [32] - Xinyuan Technology's shareholders plan to reduce their holdings by up to 3.18% of the company's shares [60]